IL17A and inflammatory bowel disease: Anti-IL17 treatments such as Ixekizumab, Brodalumab, or Secukinumab are FDA-approved and widely used in the treatment of psoriasis61 but, paradoxically, the use of IL17 blockers to treat IBD has been shown to exacerbate symptoms62–64.